Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.43 |
| ▸ | ITGAV | P06756 | 13/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 9/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.43 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.43 |
| ▸ | ITGA8 | P53708 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823593 | 0.99 | ITGB3 (0.43) | KMT2AMEN1ITGB3ITGAVITGB6 | |
| SCHEMBL7824836 | 0.97 | ITGB3 (0.44) | KMT2AMEN1ITGB3ITGAVITGB6 | |
| SCHEMBL7835830 | 0.90 | ITGB3 (0.47) | KMT2AMEN1ITGB3ITGAVITGB6 | |
| SCHEMBL6778020 | 0.89 | ITGB3 (0.48) | KMT2AMEN1ITGB3ITGAVITGB6 | |
| SCHEMBL7341395 | 0.88 | MEN1 (0.42) | KMT2AMEN1ITGB3ITGAVITGB6 | |
| SCHEMBL6777155 | 0.86 | ITGB3 (0.48) | KMT2AMEN1ITGB3ITGAVITGB6 | |
| SCHEMBL7833937 | 0.85 | ITGB3 (0.60) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7345970 | 0.85 | ITGB3 (0.47) | KMT2AMEN1ITGB3ITGAVITGB6 | |
| SCHEMBL7836758 | 0.84 | NLRP3 (0.41) | KMT2AMEN1ITGB3ITGAVITGB6 | |
| SCHEMBL7823590 | 0.84 | ITGB3 (0.48) | KMT2AMEN1ITGB3ITGAVITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | claimed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |